We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

By LabMedica International staff writers
Posted on 13 Apr 2015
Print article
The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology and to extend targeted therapeutics programs.

With the incorporation of this proteomic capability, nCounter Analysis System will hold a unique distinction of having capabilities for concurrent genomic and proteomic analysis. "These types of assays are designed to provide a powerful tool for comprehensively probing tumor biology, with potential to capture the biology needed to optimize the use of new cancer therapeutics, especially in the dynamic field of immuno-oncology, where matching patients with the right combination of therapies is critical," said Gordon Mills, MD, PhD, chair of Systems Biology at MD Anderson, and co-director of the Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy. Dr. Mills will lead the collaboration effort.

NanoString’s beta launch of the first panel for simultaneous measurement of gene and protein expression on April 18–22, 2015, at the American Association for Cancer Research (AACR) Annual Meeting in Philadelphia (PA, USA) included a talk by Joe Beechem, PhD, titled "Simultaneous multi-omic measurement of gene fusions, mRNA, and proteins at 800-plex using single-molecule optical barcodes."

nCounter Analysis System is an automated, easy-to-use platform that utilizes a novel digital barcoding chemistry to deliver high-precision multiplexed assays across various research applications. nCounter technology uses color-coded molecular barcodes that can hybridize directly to many different types of target molecules. Assays are enzyme-free and capable of generating high-quality results from challenging sample types, including FFPE tissue.

"In collaboration with experts at MD Anderson, we will be adding a new proteomic dimension to [our] assays, aiming to demonstrate their potential to inform drug development and selection,” said Brad Gray, president and CEO, NanoString Technologies.

Under the terms of the agreement, NanoString is granted rights to research and diagnostic content developed within the scope of the collaboration. Key partnership objectives include: development of multi-omic assays and signatures that profile key oncology disease pathways and immune response from tumor tissue; incorporation of these multi-omic assays into select clinical studies at MD Anderson to predict and monitor response to therapies (both as single agents and combinations); and identification of clinically actionable proteomic markers across multiple tumor types.

Related Links:

NanoString Technologies
University of Texas MD Anderson Cancer Center


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Urine Bone Markers Control
Lyphochek Urine Bone Markers Control
New
Flow Cytometer
BF – 710

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The bowel cancer breakthrough could result in better treatment outcomes (Photo courtesy of 123RF)

New RNA Molecules Can Help Predict Bowel Cancer Return Recurrence

Colorectal cancer accounts for 10% of all cancer-related deaths worldwide and was ranked as the second most common cause of cancer death in the United States in 2022. Currently, clinicians face diagnostic... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image

AI-Based Method Shows Promise for Pathological Diagnosis of Hereditary Kidney Diseases

Alport syndrome is a hereditary kidney disorder characterized by kidney dysfunction, sensorineural hearing loss, and ocular abnormalities. Early in the disease, patients experience hematuria, which is... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.